Keyphrases
Adult Male
20%
Anti-inflammatory Activity
100%
Anti-inflammatory Agents
20%
Anti-inflammatory Effect
20%
Astroglial Cells
20%
Behavioural Expression
20%
Brain Disorders
20%
C57BL
20%
Chemokine (C-C motif) Ligand 2 (CCL2)
20%
Chemokine Expression
40%
Clinical Model
20%
CXCL10
20%
Enzyme-linked Immunosorbent Assay (ELISA)
20%
Glial Fibrillary Acidic Protein
20%
In Vitro Study
20%
Inflammatory Chemokines
20%
Inflammatory Pathways
40%
Inhibitory Effect
20%
Interferon-induced Protein
20%
Interleukin-6
20%
Lipopolysaccharide
100%
Lipopolysaccharide-induced
80%
Lipopolysaccharide-induced Inflammation
100%
MAPK Expression
20%
Mediating Effect
20%
Monocyte Chemoattractant protein-1 (MCP-1)
20%
Mouse Model
100%
Mu-opioid Receptor Antagonist
20%
Neuroinflammation
60%
Nuclear factor-κB
20%
Nuclear factor-κB p65
20%
Open Field Test
20%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
60%
Protein Expression
20%
Receptor-independent
20%
Sickness Behavior
60%
Spleen
60%
Temporal Importance
20%
Therapeutic Potential
20%
Therapeutic Strategies
20%
Western Blot
20%
β-funaltrexamine
20%
μ-opioid Receptor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Inflammatory Drug
100%
Antiinflammatory Activity
12%
Antiinflammatory Agent
12%
Beta Funaltrexamine
12%
Brain Disease
12%
C57BL 6 Mouse
12%
Chemokine
37%
Cytokine
12%
Disease
37%
Enzyme-Linked Immunosorbent Assay
12%
Glial Fibrillary Acidic Protein
12%
Immunoglobulin Enhancer Binding Protein
25%
Interferon
12%
Interleukin 6
25%
Lipopolysaccharide
100%
Lipopolysaccharide-Induced Inflammation
100%
Lipopolysaccharide-Induced Neuroinflammation
12%
Mitogenic Agent
12%
Monocyte Chemotactic Protein 1
12%
Mouse Model
100%
Mu Opiate Receptor Antagonist
12%
Nervous System Inflammation
25%
Phosphotransferase
12%
Western Blot
12%
μ-Opioid Receptor
12%
Medicine and Dentistry
Antiinflammatory Activity
100%
Antiinflammatory Agent
12%
Beta Funaltrexamine
12%
Brain Disease
12%
Chemokine
37%
Cytokine
12%
Enzyme Linked Immunosorbent Assay
12%
Glial Fibrillary Acidic Protein
12%
Illness Behavior
37%
Immunoglobulin Enhancer Binding Protein
25%
In Vitro
12%
Interferon
12%
Interleukin 6
25%
Lipopolysaccharide
100%
Lipopolysaccharide-Induced Inflammation
100%
Lipopolysaccharide-Induced Neuroinflammation
12%
Mitogenic Agent
12%
Monocyte Chemotactic Protein 1
12%
Mu Opiate Receptor Antagonist
12%
Neuroinflammation
25%
p38 Mitogen-Activated Protein Kinase
25%
Phosphotransferase
12%
Protein Expression
12%
Western Blotting
12%
μ-Opioid Receptor
12%
Neuroscience
P38 Mitogen-Activated Protein Kinases
20%